sigma-aldrich (SIAL) Key Developments
Sigma-Aldrich Corporation Announces Agreement with Public Health England to Manufacture and Supply NCTC/NCPF Certified Reference Materials
Aug 27 15
Sigma-Aldrich Corporation announced it has signed an agreement with Public Health England to manufacture and supply bacterial and fungal NCTC/NCPF Certified Reference Materials in LENTICULE disc format worldwide for use as controls in food, water, environmental and clinical testing microbiology laboratories. Each CRM LENTICULE disc consists of a stipulated level of a pure culture of viable bacteria or fungi in a control-dried water-soluble matrix. The bacterial and fungal strains are prepared directly from strains selected from PHE's National Collection of Type Cultures and National Collection of Pathogenic Fungi.
Sigma-Aldrich Corporation Declares Quarterly Dividend, Payable on September 15, 2015
Aug 24 15
Sigma-Aldrich Corporation announced a quarterly cash dividend of $0.23 per share. On August 24, 2015, the company's Board of Directors conditionally approved this dividend to shareholders of record on September 1, 2015. Payment of this dividend will be made on September 15, 2015, so long as the transaction by which Merck KGaA is to acquire all of the outstanding shares of the company has not closed on that date or a date prior thereto.
Sigma-Aldrich Corporation(NasdaqGS:SIAL) dropped from NASDAQ-100 Index
Aug 2 15
Sigma-Aldrich Corporation will be removed from NASDAQ-100 Index.
Sigma-Aldrich Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Jul 30 15
Sigma-Aldrich Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported sales of $697 million compared to $701 million a year ago. Operating income was $169 million compared to $184 million a year ago. Income before income taxes was $168 million compared to $184 million a year ago. Net income was $120 million or $0.98 per diluted share $133 million or $1.11 per diluted share a year ago. Adjusted net income was $123 million or $1.01 per diluted share compared to $133 million or $1.11 per diluted share a year ago. Adjusted operating income was $173 million compared to $185 million a year ago.
For the six months, the company reported sales of $1,373 million compared to $1,390 million a year ago. Operating income was $344 million compared to $358 million a year ago. Income before income taxes was $343 million compared to $357 million a year ago. Net income was $246 million or $2.02 per diluted share $259 million or $2.16 per diluted share a year ago. Adjusted net income was $251 million or $2.06 per diluted share compared to $260 million or $2.17 per diluted share a year ago. Adjusted operating income was $351 million compared to $360 million a year ago. Net cash provided by operating activities was $307 million compared to $287 million a year ago. Capital expenditures were $55 million compared to $55 million a year ago. Free cash flow for the first six months of 2015 was $252 million, of which $55 million was returned to shareholders through dividends.
GenapSys, Inc. Partners with Sigma-Aldrich Corporation
Jul 1 15
GenapSys, Inc. has partnered with Sigma-Aldrich Corporation to co-market GenapSys' Gene Electronic Nano-Integrated Ultra-Sensitive (Genius(TM)) system, a personal deoxyribonucleic acid (DNA) sequencer.